argenx (ADR) (ARGX)
Develops antibody medicines for severe autoimmune diseases around the VYVGART franchise.
$972.77
vs last close−15.43 (−1.56%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 45.65% | 28.25M ADS | |
|---|---|---|---|
| 527 holders · as of Jun 30, 2026 | |||
| Other | 54.35% | 33.63M ADS | |
| remainder | |||
61.88M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
527 holders · 28.25M shares · 84 new positions · 266 increased · 167 reduced · 52 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 5.23M | 8.45% | +240.4K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.68M | 4.33% | −696.9K | Aug 14, 2026 |
| Jupiter Topco LLC | 2.47M | 4.00% | +2.47Mnew | Aug 14, 2026 |
| Capital World Investors | 2.20M | 3.55% | −56.4K | Aug 12, 2026 |
| Artisan Partners Limited Partnership | 1.51M | 2.44% | +40.8K | Aug 13, 2026 |
| Avoro Capital Advisors LLC | 1.00M | 1.62% | 0 | Aug 14, 2026 |
| Wellington Management Group LLP | 930.5K | 1.50% | −90.9K | Aug 14, 2026 |
| BlackRock, Inc. | 777.2K | 1.26% | −31.1K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 8.70% | 5.41M | 13G | May 6, 2026 |
| T. Rowe Price Associates, Inc. | 6.00% | 3.65M | 13G | Nov 14, 2025 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.